Vor Biopharma Earnings Call Transcripts
Fiscal Year 2026
-
Telitacicept, a BAFF/APRIL inhibitor, is advancing in global phase III trials for myasthenia gravis and Sjögren's disease, showing best-in-disease efficacy and a strong safety profile. The company is well-funded through 2028 and targets multi-billion dollar markets in both indications.
-
A strategic pivot to autoimmune diseases is underway, with telitacicept as the lead asset showing strong efficacy and safety in large patient populations. Global Phase 3 trials in myasthenia gravis and Sjögren's are advancing, supported by a $450M cash runway and a seasoned leadership team.
Fiscal Year 2025
-
Management highlighted strong late-stage data for their BAFF/APRIL inhibitor in MG and Sjögren's, with plans to start a global phase 3 for Sjögren's next year. They aim to address high placebo rates in global trials and have a $300M cash runway to fund key milestones.
-
Bispecific BAFF/APRIL targeting enables broad B cell modulation with strong efficacy in Sjogren's and gMG, supported by robust phase III data and a balanced safety profile. Commercial focus is on leading in gMG and building the Sjogren's market, with $315M in cash funding operations through mid-2027.
-
A robust phase III study in China showed telitacicept significantly improved systemic and symptomatic outcomes in primary Sjögren’s disease, with a strong safety profile and no confounding background therapies. The dual BAFF/APRIL mechanism offers a new benchmark for efficacy and positions the therapy for global expansion.
-
Vor 2.0 is focused on telitacicept, a dual BAFF/APRIL inhibitor with strong late-stage data in myasthenia gravis and Sjögren’s. The company is advancing global phase III trials, leveraging robust China data, and expects key data readouts in late 2023.
-
Leadership outlined a strategy centered on telitacicept, a late-stage dual BAFF/APRIL inhibitor with strong clinical and commercial validation in China. Key milestones include global phase III trials in MG and Sjögren’s, robust upcoming data, and a solid financial position to support expansion.
-
Gene-edited stem cell transplants for AML are showing promising early clinical results, with improved relapse-free survival and a broadened therapeutic window for Mylotarg. Key regulatory milestones have been achieved, and pivotal trial data are expected in 2025. Additional pipeline programs include multi-antigen CAR-Ts and a CD45-directed ADC.
Fiscal Year 2024
-
VBP101 trial data show trem-cel enables rapid engraftment, effective shielding from Mylotarg toxicity, and promising relapse-free survival in high-risk AML. The safety profile is favorable, and a phase III trial design has FDA support. Investigators highlight the platform's transformative potential.
-
The session highlighted progress in AML and MDS trials, with new data on trem-cel and Mylotarg showing extended relapse-free survival and safety at higher doses. Plans for a randomized phase III trial, pipeline expansion, and a strong cash position were discussed.
-
Trem-cel plus post-transplant Mylotarg in high-risk AML showed rapid engraftment, stable blood counts, and promising relapse-free survival compared to historical controls. Only two relapses occurred among Mylotarg-treated patients, both with TP53 mutations. Plans are underway for a pivotal trial at the 2 mg/m² Mylotarg dose.